CSI Market
Sign In | Register

Silexion Therapeutics (SLXN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SLXN quarterly Cash Flow →
A period-by-period view of cash flow from Silexion Therapeutics to helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024)
Operating Activities
Income-11.91
Depreciation & amortization0.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.13
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Gain Loss On Termination Of Lease-
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.24
Increase (Decrease) in Accounts Payable, Trade-0.14
Increase (Decrease) in Accrued Liabilities0.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.40
Other Working Capital0.01
Other Noncash Income (Expense)0.34
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.01
Discontinued operations0.00
Net Cash flow from Operating Activities-10.82
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments-0.01
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired in Excess of Payments to Acquire Business0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.43
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents1.27
Restricted Cash0.08
Operating Lease Termination-
Conversion Of Preferred Shares-
Conversion Of Warrants To Preferred Shares On A Cashless Basis-
Proceeds From Exercise Of Prefunded Options-
Proceeds From Issuance Of Ordinary Shares Upon Public Offering11.00
Proceeds From Issuance Of Ordinary Shares Upon Warrants Inducement5.04
Payment Of Underwriters Promissory Note-0.70
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities15.64
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.83
Total Cash Flow4.81
4 historic quarters locked

Sign in to unlock the full Silexion Therapeutics cash flow history.

Sign In Create Free Account

About Silexion Therapeutics Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 17, 2026
  • Source: zk2634529.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001178913-26-000953

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License